Patents Examined by Ilia I Ouspenski
  • Patent number: 10723799
    Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: July 28, 2020
    Assignee: I-Mab Biopharma US Limited
    Inventors: Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
  • Patent number: 10660953
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: May 26, 2020
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Weihsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
  • Patent number: 10647770
    Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: May 12, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro Shibayama, Masamichi Imai
  • Patent number: 10633450
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Patent number: 10633446
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: April 28, 2020
    Assignees: INSERM (Institut National de la Santéet de la Recherche Medicale), Institut Jean Paoli & Irene Calmettes, Universitéd'Aix-Marseille, Universite Claude Bernerd—Lyon }, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 10626174
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 21, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Patent number: 10626176
    Abstract: Provided herein are embodiments relating to therapeutic applications of B7-H4 antibodies.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: April 21, 2020
    Assignee: JOUNCE THERAPEUTICS, INC.
    Inventors: Sriram Sathyanarayanan, Tatiana Novobrantseva, Virna Cortez-Retamozo
  • Patent number: 10618963
    Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 14, 2020
    Assignee: Yeda Research and Development Co. Ltd
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Patent number: 10611836
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 7, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Patent number: 10604575
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 31, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 10604576
    Abstract: The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: March 31, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Nikole Sandy Nee Waddell, Stephen D. Gillies, Volker Germaschewski, Cassandra van Krinks, Ian Kirby, Miha Kosmac, Steve Arkinstall, Thomas Gallagher
  • Patent number: 10590199
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: March 17, 2020
    Assignee: CHECKPOINT THERAPEUTICS, INC.
    Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
  • Patent number: 10590183
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: March 17, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
  • Patent number: 10584168
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: March 10, 2020
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Patent number: 10584170
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: March 10, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 10577423
    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: March 3, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
  • Patent number: 10570204
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: February 25, 2020
    Assignees: The Medical College of Wisconsin, Inc., Novartis AG
    Inventors: Bryon Duane Johnson, Robert Millman
  • Patent number: 10570213
    Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: February 25, 2020
    Assignee: Genentech, Inc.
    Inventors: Jeong Kim, Jeanne Cheung
  • Patent number: 10570203
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: February 25, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • Patent number: 10550173
    Abstract: The present invention is directed to PVRIG polypeptides and their uses.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Compugen, Ltd.
    Inventors: Mark White, Sandeep Kumar, Christopher Chan, Spencer Liang, Lance Stapleton, Andrew W. Drake, Yosi Gozlan, Ilan Vaknin, Shirley Sameah-Greenwald, Liat Dassa, Zohar Tiran, Gad S. Cojocaru, Amir Toporik, Yossef Kliger, Ofer Levy, Arthur Machlenkin, Sergey Nemzer, Yair Benita, Amit Novik